These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 7976857

  • 21. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.
    Prescott S, Jackson AM, Hawkyard SJ, Alexandroff AB, James K.
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S91-3. PubMed ID: 11010831
    [Abstract] [Full Text] [Related]

  • 22. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR, Noel JC, Fayt I, Drowart A, Van Vooren JP, Huygen K, Simon J, Schulman CC.
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [Abstract] [Full Text] [Related]

  • 23. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T, Alter A, Wiechno P.
    Urol Int; 2008 Mar; 80(1):74-9. PubMed ID: 18204238
    [Abstract] [Full Text] [Related]

  • 24. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
    Kaczmarek P, Błaszczyk J, Fijałkowski P, Sierakowska-Fijałek A, Niemirowicz J, Kasprzak A, Baj Z.
    Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
    [Abstract] [Full Text] [Related]

  • 25. Oxidative stress of red blood cells during Bacillus Calmette-Guerin intravesical instillations.
    Mitropoulos D, Deliconstantinos G, Zervas A, Giannopoulos A, Kyriakou G, Dimopoulos C.
    In Vivo; 2000 Oct; 14(6):721-4. PubMed ID: 11204488
    [Abstract] [Full Text] [Related]

  • 26. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
    De Boer EC, Rooijakkers SJ, Schamhart DH, Kurth KH.
    J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V, Pode D, Pikarsky E, Mandelboim O.
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Response of lymphocytes and cytokines in patients with superficial bladder cancer treated with 1 mg of BCG vaccine instillations].
    Rivera P, Inostroza J, Orio M.
    Actas Urol Esp; 1996 Oct; 20(9):812-7. PubMed ID: 9065092
    [Abstract] [Full Text] [Related]

  • 34. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
    Steinbach F, Schuster F.
    Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
    [Abstract] [Full Text] [Related]

  • 35. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
    Iturralde Codina A, Beyríe Tamayo W, Gozá León F, Muñoz YI.
    Arch Esp Urol; 2004 Aug; 57(6):606-18. PubMed ID: 15382436
    [Abstract] [Full Text] [Related]

  • 36. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M, Guerin F, Amsellem-Ouazana D, Saighi D, Debre B, Zerbib M.
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [Abstract] [Full Text] [Related]

  • 37. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911.
    Vegt PD, van der Meijden AP, Sylvester R, Brausi M, Höltl W, de Balincourt C.
    J Urol; 1997 Apr; 157(4):1246-9. PubMed ID: 9120912
    [Abstract] [Full Text] [Related]

  • 38. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.
    Biot C, Rentsch CA, Gsponer JR, Birkhäuser FD, Jusforgues-Saklani H, Lemaître F, Auriau C, Bachmann A, Bousso P, Demangel C, Peduto L, Thalmann GN, Albert ML.
    Sci Transl Med; 2012 Jun 06; 4(137):137ra72. PubMed ID: 22674550
    [Abstract] [Full Text] [Related]

  • 39. [Preventive treatment of superficial tumors of the bladder using intravesical BCG. Review].
    Patard JJ, Chopin DK.
    Ann Urol (Paris); 1993 Jun 06; 27(1):24-30. PubMed ID: 8470876
    [Abstract] [Full Text] [Related]

  • 40. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
    Yamada Y, Washida H, Tozawa K, Honma H, Kang K.
    Hinyokika Kiyo; 1994 Jul 06; 40(7):575-9. PubMed ID: 8085517
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.